Fusen Pharmaceutical Company Limited provided Group earnings guidance for the six months ended 30 June 2019. The board of directors of the Company announced that, based on the unaudited consolidated management accounts for the six months ended 30 June 2019 of the Group and the information currently available to the Company, the Group is expected to record a decline by more than 40% in the profit attributable to owners of the Company for the six months ended 30 June 2019 (the ``Interim Period''), as compared with the corresponding period last year.